Score Breakdown
Dilution Forecast
Market Data
Source-Backed Evidence Depth
This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.
| Field | Current Value | Basis |
|---|---|---|
| DilutionScore | 87/100 | DilutionWatch score record |
| Shares Outstanding | 4.02M | Verified float table or market cache |
| Public Float | 3.17M | Verified float table or market cache |
| Market Cap | $3.58M | Market data cache |
| Cash Runway | 6.0 months | DilutionWatch score inputs |
| Shelf Capacity | None in current score inputs | SEC-derived dilution fields |
| ATM Capacity | None in current score inputs | SEC-derived dilution fields |
| Outstanding Warrants | 5.42M | SEC-derived dilution fields |
Recent source-backed SEC insight records available on this page: 2.
Recent SEC source mix: XBRL 2.
The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.
Institutional Holdings
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Recent SEC Activity
Recent News
Factual DRMA Dilution Snapshot
Dermata Therapeutics, Inc. (DRMA) has a DilutionScore of 87/100, rated Critical dilution risk. Score date: October 13, 2026.
- Stored outstanding warrants: 5.4M.
- Recent SEC activity tracked for DRMA: xbrl on 2026-08-11; xbrl on 2023-02-21.
- Score coverage note: Debt is unavailable or zero in the market-data feed while convertible risk is high; convertible overhang is shown separately and is not reconciled to the Debt field.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
DilutionScore History — Last 90 Days
DRMA's DilutionScore is currently 87/100 (Critical risk), with 2 score changes tracked over 89 days. The score improved from 71/100 (High risk).
| Period | Score | Risk Level | Duration |
|---|---|---|---|
| Aug 22 – Oct 13, 2026 | 87/100 | CRITICAL | 53 days |
| Aug 14 – Aug 21, 2026 | 71/100 | HIGH | 7 days |
| Jul 16 – Aug 13, 2026 | 87/100 | CRITICAL | 29 days |
Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.
Share Dilution History
DRMA shares outstanding have increased 25.8% from 3.20M (Mar 2026) to 4.02M (Apr 2026). Each increase represents potential dilution to existing shareholders.
| Date | Shares Outstanding | Public Float | Change |
|---|---|---|---|
| Apr 26, 2026 | 4.02M | 3.17M | ▲ 8.16% |
| Apr 07, 2026 | 4.02M | 2.93M | ▼ 0.04% |
| Apr 01, 2026 | 3.20M | 2.93M | ▲ 51.37% |
| Mar 30, 2026 | 3.20M | 1.94M | ▲ 291.85% |
Share counts sourced from verified regulatory filings. Increases indicate dilution events.
Related Stocks — CRITICAL Risk
Other CRITICAL dilution risk stocks tracked by DilutionWatch with similar profiles:
Score Coverage Note
- Debt is unavailable or zero in the market-data feed while convertible risk is high; convertible overhang is shown separately and is not reconciled to the Debt field.
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.